What has happened is that the patient ends up going to their provider, a physician, a pharmacist, a nurse practitioner, and has to be now put on a new therapy with unknown consequences
GLP-1 analogs and weight regulation Weight control is key to combatting obesity and T2D
As popularity and demand continue to rise for GLP-1s, so do costs on both a per-unit and total-spend basis
GLP-1 RAs are not contraindicated in patients with prior atrial fibrillation, although the modest heart rate increase warrants monitoring
However, recently there has been a crackdown on this practice, with drug companies sending cease and desist letters to compounding pharmacies, telehealth practices, and medspas who are creating their own versions of these drugs (thats how you know its a money-making drug!)